Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...

U.S. Market Leads with 74% Share in 2023 Valued at USD 2.71 Billion, Driven by Biotech Innovation, Favorable FDA Approvals, and Rising Chronic Disease Incidence.Austin, July 18, 2025 (GLOBE NEWSWIRE) ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain branded drugs ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

WeightWatchers Completes Financial Reorganization, Strengthens Leadership, and Expands Program Innovation to Support Women Through Menopause ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

The obstructive sleep apnea (OSA) market is being propelled by the rapid evolution of early detection and diagnostic tools. Technologies like home sl ...